The unguarded X hypothesis explains male‑biased mortality by highlighting the lack of a homologous X to mask deleterious mutations, yet it does not address how X dosage directly influences cellular metabolic pathways that drive aging. Recent data show that XX individuals exhibit lower basal pro‑inflammatory cytokine production despite higher TLR7 expression, suggesting a buffering mechanism that tempers inflammaging [4]. Notably, the NAD+ biosynthetic enzyme NAMPT is encoded on the X chromosome (Xq12) and escapes X‑chromosome inactivation in a subset of cells, creating a mosaic of NAMPT expression levels in XX tissues [6]. We hypothesize that this escape‑driven NAMPT mosaicism sustains higher intracellular NAD+ pools in XX cells, thereby enhancing SIRT1‑dependent deacetylation of NF‑κB and NLRP3 inflammasome components, which suppresses chronic inflammation and preserves mitochondrial function. In XY cells, a single active X yields uniform, lower NAMPT expression, resulting in reduced NAD+, diminished SIRT1 activity, and heightened inflammaging.

Mechanistically, elevated NAD+ fuels SIRT1‑mediated deacetylation of PGC‑1α, promoting mitochondrial biogenesis and oxidative phosphorylation efficiency. Simultaneously, SIRT1 deacetylates the RelA subunit of NF‑κB, reducing its transcriptional activity and limiting IL‑6, TNF‑α, and IL‑1β secretion. The combined effect is a lower inflammatory set‑point and improved resistance to oxidative stress, both hallmarks of longevity. Age‑related skewing of XCI diminishes the proportion of cells escaping inactivation, leading to a decline in NAMPT‑high mosaicism, a drop in NAD+, and a rise in inflammaging—mirroring observations that centenarians retain balanced XCI [5].

Testable predictions:

1. XX mice and humans will show higher tissue‑specific NAD+ levels and a greater fraction of NAMPT‑positive cells than XY counterparts, measurable by immunofluorescent co‑staining for NAMPT and XIST RNA.
2. Pharmacological inhibition of NAMPT (e.g., with FK866) in XX mice will erase the sex‑difference in basal cytokine production and accelerate age‑related frailty, while NAMPT supplementation (e.g., NR or NMN) in XY mice will raise NAD+, reduce inflammaging markers, and extend median lifespan.
3. Inducing uniform XCI escape of NAMPT in XY mice via CRISPR‑based activation of the X‑linked promoter will increase mosaicism, elevate NAD+, and confer XX‑like resistance to LPS‑induced sepsis.
4. Longitudinal human cohorts will reveal that increasing XCI skewing (quantified by allele‑specific RNA‑seq) correlates with declining blood NAD+ levels and rising plasma IL‑6/TNF‑α, independent of hormonal status.

Falsification outcomes: If NAMPT expression does not escape XCI in relevant tissues, or if modulating NAMPT fails to alter NAD+ levels, inflammaging, or lifespan in the predicted directions, the hypothesis would be refuted. Conversely, confirmation would position X‑linked metabolic mosaicism—not merely immune gene dosage—as a central mechanism by which the X chromosome governs longevity, shifting focus from hormonal explanations to cell‑autonomous metabolic regulation.